Study Phase 4

A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia

  • PDF icon for CSR Summary CSR Summary Not Available
  • Globe symbol for NCT Number NCT01394991
  • Notebook for Primary Citation Primary Citation Not Yet Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameEpoetin alfaProduct NamePROCRIT®Therapeutic AreaBlood and Lymph ConditionsEnrollment504% FemaleN/A% WhiteN/A
Product ClassHematologic AgentsSponsor Protocol NumberEPOANE4008Data PartnerJohnson & JohnsonCondition StudiedAnemia, NeoplasmsMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.